PT2280717T - Agente terapêutico para doenças anaeróbias - Google Patents

Agente terapêutico para doenças anaeróbias

Info

Publication number
PT2280717T
PT2280717T PT09733604T PT09733604T PT2280717T PT 2280717 T PT2280717 T PT 2280717T PT 09733604 T PT09733604 T PT 09733604T PT 09733604 T PT09733604 T PT 09733604T PT 2280717 T PT2280717 T PT 2280717T
Authority
PT
Portugal
Prior art keywords
therapeutic agent
anaerobic diseases
anaerobic
diseases
therapeutic
Prior art date
Application number
PT09733604T
Other languages
English (en)
Inventor
Shimatani-Shibata Yuko
Shimizu Hitomi
Yonekura Hiromi
Sasaki Takayuki
Original Assignee
Anaeropharma Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaeropharma Science Inc filed Critical Anaeropharma Science Inc
Publication of PT2280717T publication Critical patent/PT2280717T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT09733604T 2008-04-17 2009-04-17 Agente terapêutico para doenças anaeróbias PT2280717T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12452808P 2008-04-17 2008-04-17

Publications (1)

Publication Number Publication Date
PT2280717T true PT2280717T (pt) 2018-10-04

Family

ID=40792658

Family Applications (2)

Application Number Title Priority Date Filing Date
PT97330740T PT2274422T (pt) 2008-04-17 2009-04-16 Vetor de expressão
PT09733604T PT2280717T (pt) 2008-04-17 2009-04-17 Agente terapêutico para doenças anaeróbias

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT97330740T PT2274422T (pt) 2008-04-17 2009-04-16 Vetor de expressão

Country Status (12)

Country Link
US (3) US8383398B2 (pt)
EP (2) EP2274422B1 (pt)
JP (3) JP5735804B2 (pt)
KR (3) KR101674977B1 (pt)
CN (2) CN102046791B (pt)
CA (2) CA2721653C (pt)
DK (2) DK2274422T3 (pt)
ES (2) ES2628378T3 (pt)
HU (2) HUE033561T2 (pt)
PL (2) PL2274422T3 (pt)
PT (2) PT2274422T (pt)
WO (2) WO2009128272A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130095072A1 (en) * 2010-01-29 2013-04-18 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
EP2274422B1 (en) * 2008-04-17 2017-03-15 Anaeropharma Science, Inc. Expression vector
US9730968B2 (en) 2008-04-17 2017-08-15 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
US8338162B2 (en) * 2009-04-17 2012-12-25 Anaeropharma Science, Inc. Obligately anaerobic mutant lactic acid bacterium and preparation method therefor, and expression vector functioning in obligately anaerobic lactic acid bacterium
EP2910636B1 (en) 2010-01-29 2018-01-17 Anaeropharma Science, Inc. Transformation plasmid
CN103958680A (zh) * 2011-07-13 2014-07-30 阿内罗药物科学株式会社 缺血性疾病治疗药
SG11201704450UA (en) 2014-12-03 2017-06-29 Anaeropharma Science Inc Coexpression plasmid
SG11201705915VA (en) * 2015-01-19 2017-08-30 Univ Shinshu Therapeutic agent for ischemic diseases
US20220281998A1 (en) 2019-08-28 2022-09-08 Azusapharma Sciences, Inc. Bifidobacterium spp. expressing and secreting diabody-type bsab
CN112999215A (zh) * 2019-12-20 2021-06-22 复旦大学 呋喃酮糖苷类化合物的应用
CN115400154A (zh) * 2022-08-10 2022-11-29 深圳未知君生物科技有限公司 长双歧杆菌在制备治疗自闭症谱系障碍的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8713601D0 (en) * 1987-06-10 1987-07-15 Unilever Plc Fermentation
WO1991009131A1 (en) * 1989-12-20 1991-06-27 Valio Finnish Cooperative Dairies Association Cloning vector for use in lactic acid bacteria
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
US6416754B1 (en) 1994-03-03 2002-07-09 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
TW357191B (en) * 1996-06-04 1999-05-01 Food Industry Development Res Institute Bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method the invention relates to bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method
JP2000060541A (ja) * 1998-08-27 2000-02-29 Fuyuki Mitsuyama ビフィズス菌増殖促進物質と整腸物質とビフィズス菌製剤
JP3642755B2 (ja) * 2000-09-21 2005-04-27 純 天野 嫌気性菌を用いた遺伝子治療用医薬
US20020054865A1 (en) * 2000-09-21 2002-05-09 Minoru Fujimori Anaerobic bacterium as a drug for cancer gene therapy
CA2432797C (en) * 2000-12-18 2014-02-04 David J. Yang Local regional chemotherapy and radiotherapy using in situ hydrogel
KR100457879B1 (ko) * 2001-02-24 2004-11-18 주식회사 비피도 비피도박테리움 유래 신규 플라스미드, 이를 이용한 재조합 발현 벡터 및 형질전환 방법
SG158077A1 (en) * 2004-11-24 2010-01-29 Anaeropharma Science Inc Novel shuttle vector
KR100989267B1 (ko) * 2005-01-21 2010-10-20 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 유착 관절낭염을 치료하는 방법
DK1867714T3 (da) 2005-04-08 2013-12-09 Anaeropharma Science Inc 5-fluoruracilresistente bakterier og fremgangsmåde til produktion deraf
EP2007715A2 (en) * 2006-03-27 2008-12-31 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Tetracycline compounds and methods of treatment
US20090291469A1 (en) * 2006-04-13 2009-11-26 David Peter R Compositions and Methods for Producing Fermentation Products and Residuals
PT2468861E (pt) * 2006-05-24 2014-12-05 Anaeropharma Science Inc Método de construção de suporte de tranporte de genes
EP2274422B1 (en) * 2008-04-17 2017-03-15 Anaeropharma Science, Inc. Expression vector

Also Published As

Publication number Publication date
US8383398B2 (en) 2013-02-26
WO2009128272A9 (en) 2010-11-11
KR20100134765A (ko) 2010-12-23
JP5735804B2 (ja) 2015-06-17
PL2274422T3 (pl) 2017-09-29
CN102046190B (zh) 2013-03-13
HUE039768T2 (hu) 2019-02-28
WO2009128275A1 (en) 2009-10-22
DK2274422T3 (en) 2017-07-03
JP2011518112A (ja) 2011-06-23
CN102046190A (zh) 2011-05-04
WO2009128275A9 (en) 2010-11-11
EP2280717B1 (en) 2018-05-30
US8470311B2 (en) 2013-06-25
CN102046791A (zh) 2011-05-04
ES2628378T3 (es) 2017-08-02
EP2280717A1 (en) 2011-02-09
KR20110021784A (ko) 2011-03-04
KR101674977B1 (ko) 2016-11-10
DK2280717T3 (en) 2018-09-10
CA2721653C (en) 2018-03-20
JP5514735B2 (ja) 2014-06-04
EP2274422A1 (en) 2011-01-19
WO2009128272A4 (en) 2010-02-18
US20110110893A1 (en) 2011-05-12
KR20160102584A (ko) 2016-08-30
WO2009128275A4 (en) 2010-02-18
CA2721664A1 (en) 2009-10-22
PT2274422T (pt) 2017-06-28
HUE033561T2 (hu) 2017-12-28
EP2274422B1 (en) 2017-03-15
CA2721653A1 (en) 2009-10-22
US20130122582A1 (en) 2013-05-16
WO2009128272A1 (en) 2009-10-22
JP2011517929A (ja) 2011-06-23
CN102046791B (zh) 2013-09-18
ES2686080T3 (es) 2018-10-16
KR101671283B1 (ko) 2016-11-02
US20090264513A1 (en) 2009-10-22
JP2015091243A (ja) 2015-05-14
PL2280717T3 (pl) 2018-10-31
CA2721664C (en) 2018-01-23
JP6089025B2 (ja) 2017-03-01

Similar Documents

Publication Publication Date Title
GB0811304D0 (en) Therapeutic agents
EP2320907A4 (en) THERAPEUTIC COMPOUNDS
EP2343066A4 (en) THERAPEUTIC AGENT FOR HEPATITIS C
PL2280717T3 (pl) Środek terapeutyczny dla chorób beztlenowych
GB0811643D0 (en) New therapeutic agents
EP2268285A4 (en) THERAPEUTIC COMPOUNDS
EP2300011A4 (en) METHODS AND THERAPEUTIC COMPOUNDS
GB0819593D0 (en) Therapeutic agents
GB0806794D0 (en) Therapeutic compounds
GB0821693D0 (en) Therapeutic agents
GB0813740D0 (en) Therapeutic compounds
GB0812309D0 (en) Therapeutic agents
GB0805818D0 (en) Therapeutic agents
GB0804755D0 (en) Therapeutic compounds
IL209006A0 (en) Therapeutic agent for male sterility
GB0801080D0 (en) Therapeutic agents
GB0801081D0 (en) Therapeutic agents
GB0900484D0 (en) Therapeutic agent
EP2486929A4 (en) ANTI-TUMOR THERAPEUTIC AGENT
EP2454276A4 (en) THERAPEUTIC AGENTS
EP2210878A4 (en) THERAPEUTIC AGENT AGAINST TRPV1-MEDIATED DISEASES
ZA201007839B (en) Therapeutic agent for pain
GB0811715D0 (en) Therapeutic agents
EP2324827A4 (en) THERAPEUTIC ACTIVE FOR ANCA-ASSOCIATED VASCULITIDES
EP2500029A4 (en) THERAPEUTIC AGENT FOR DISEASES OF THE STOMACH DARM TRAKTS